|Committee Member||Employment||Consultant||Speaker’s Bureau||Ownership/ Partnership/ Principal||Personal Research||Institutional, Organizational, or Other Financial Benefit||Expert Witness|
|Jeffrey L. Anderson||Intermountain Heart Institute, Intermountain Healthcare—Associate Chief of Cardiology||None||None||None||None||None||None|
|Jonathan L. Halperin||The Cardiovascular Institute, Mount Sinai Medical Center, Division of Cardiology—Professor of Medicine||None||None||None||None||None||None|
|Alice K. Jacobs||Boston University School of Medicine—Professor of Medicine; Boston Medical Center, Department of Medicine—Vice Chair for Clinical Affairs||None||None||None||None||None||None|
This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$10,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.
According to the ACC/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) The company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) The person or a member of the person’s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document.
ACC indicates American College of Cardiology and AHA, American Heart Association.
↵∗ For transparency, the authors' comprehensive disclosure information is available as an online supplement (http://jaccjacc.cardiosource.com/acc_documents/Guidelines_Perspective_Article_Author_Comprehensive_RWI.pdf).